ReviewGastroenterology clinics of North America2022
Management of Dysplastic Barrett's Esophagus and Early Esophageal Adenocarcinoma.
Review in Gastroenterology clinics of North America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Treatment of dysplastic Barrett's esophagus using a novel over-the-scope device for hybrid argon plasma coagulation.Endoscopy · 2026Article
- Comparison of Invasive Interventions for Halting the Progression of Barrett's Esophagus.Cureus · 2026Review
- Assessment of Nutritional Risk Screening 2002 as predictors of long hospital stay in patients with upper gastrointestinal diseases.Frontiers in nutrition · 2026Article
- International Federation for Surgery for Obesity and Metabolic Disorders Position Statement on the role of Upper Gastrointestinal Endoscopy Before and After Metabolic Bariatric Surgery.Obesity surgery · 2025Article
- Photodynamic therapy in esophageal cancer: trends, innovations, and future directions from a global perspective (1985-2024).Discover oncology · 2025Article
- [Use of flexible transnasal esophagogastroscopy in patients with unclear globus sensation].HNO · 2024Article
- Endoscopic Management of Dysplastic Barrett's Oesophagus and Early Oesophageal Adenocarcinoma.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
While patients with Barrett's esophagus without dysplasia may benefit from endoscopic surveillance, those with low-grade dysplasia may be managed with either endoscopic surveillance or endoscopic eradication. Patients with Barrett's esophagus with high-grade dysplasia and/or intramucosal adenocarcinoma will generally require endoscopic eradication therapy. The management of Barrett's esophagus with dysplasia and early esophageal adenocarcinoma is predominantly endoscopic, with multiple effective methods available for the resection of raised neoplasia and ablation of flat neoplasia. High-dose proton-pump inhibitor therapy is advised during the treatment of Barrett's esophagus with dysplasia and early esophageal adenocarcinoma. After the endoscopic eradication of Barrett's esophagus and associated neoplasia, surveillance is required for the diagnosis and retreatment of recurrence or progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.